Study Evaluating the Safety, Efficacy and Pharmacokinetics of CA-008 (Vocacapsaicin)

NCT ID: NCT04203537

Last Updated: 2024-05-08

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

193 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-12-04

Study Completion Date

2020-10-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In the pilot (Part A) of this study, multiple doses of CA-008 (vocacapsaicin) were evaluated for safety, tolerability, and PK. Doses were then selected for the expanded part (Part B) of the study, where CA-008 was compared to placebo. Patients had serial assessments of safety, PK, and drug effect.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Not provided

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postsurgical Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Part A: dose ascending, placebo-controlled Part B: randomized, double-blind, placebo-controlled, parallel design
Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CA-008 36 mg

Single administration (0.3 mg/mL concentration)

Group Type ACTIVE_COMPARATOR

CA-008

Intervention Type DRUG

Local administration during surgery

CA-008 60 mg

Single administration (0.5 mg/mL concentration)

Group Type ACTIVE_COMPARATOR

CA-008

Intervention Type DRUG

Local administration during surgery

CA-008 90 mg

Single administration (0.75 mg/mL concentration)

Group Type ACTIVE_COMPARATOR

CA-008

Intervention Type DRUG

Local administration during surgery

Placebo

Single administration

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Local administration during surgery

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CA-008

Local administration during surgery

Intervention Type DRUG

Placebo

Local administration during surgery

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

vocacapsaicin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Scheduled elective Total Knee Arthroplasty (TKA) under spinal anesthesia
* Aged 18-80 years old
* ASA physical class 1, 2, or 3
* BMI \</= 42 kg/m2
* Generally healthy

Exclusion Criteria

* Concurrent condition requiring analgesic treatment during study period
* Opioid tolerant
* Known allergy to capsaicin or other study medication
* Use of prohibited medications
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Concentric Analgesics

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Daneshvari Solanki, MD

Role: PRINCIPAL_INVESTIGATOR

HD Research

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Lotus Clinical Reserach, LLC

Pasadena, California, United States

Site Status

Legent Orthopedic Hospital

Carrollton, Texas, United States

Site Status

First Surgical Hospital

Houston, Texas, United States

Site Status

Plano Surgical Hospital

Plano, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CA-PS-208

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Post-operative Efficacy and Safety Study
NCT00904085 COMPLETED PHASE3
Post-op Ketamine Study
NCT03865550 UNKNOWN NA